
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is expected to continue its growth trajectory driven by its innovative light adjustable lenses technology, which offers a customized solution for patients following cataract surgery. Despite the current challenges in utilization and margin contraction, the company's strong financials, including a gross margin of 76.1% in Q1 2026, indicate its ability to weather the storm and return to growth in the second half of 2026. Exciting developments in the overseas market also present a potential growth opportunity for the company.
Bears say
RxSight is currently facing challenges in revenue growth, with lower Light Delivery Device revenue leading to a 19% decline in overall revenue in the fourth quarter of 2025. The company is also struggling with low LDD placements, with only 25 LDDs placed in the fourth quarter. While management has expressed optimism for future growth, there are concerns around limited adoption due to the need for additional capital equipment, potential competition in the market, and the possibility of a dilutive funding round. These factors, along with a high cash burn rate, contribute to the analyst's negative outlook on RxSight's stock.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares